Stockscreener 앱 받기
4.28
0.00%
0.00
전일 마감가:
$4.28
열려 있는:
$4.31
하루 거래량:
64,408
Relative Volume:
0.21
시가총액:
$132.58M
수익:
-
순이익/손실:
$-21.24M
주가수익비율:
-
EPS:
-
순현금흐름:
$-22.47M
1주 성능:
-22.32%
1개월 성능:
-9.13%
6개월 성능:
-64.36%
1년 성능:
+0.00%
1일 변동 폭
$4.21
$4.49
1주일 범위
$4.21
$5.63
52주 변동 폭
$2.9501
$17.65
Skye Bioscience Inc Stock (SKYE) Company Profile
명칭
Skye Bioscience Inc
전화
(858) 410-0266
주소
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
SKYE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| SKYE | 12.30 | 12.89M | 0 | 0 | 0 | 0.00 |
| GOODO | 21.92 | 372.90M | 0 | 0 | 0 | 0.00 |
| PSNYW | 0.132 | 304.95M | 2.07B | -1.42B | -1.37B | -0.1344 |
| MOBBW | 0.15 | 278.60M | 0 | 0 | 0 | 0.00 |
| SHMD | 2.45 | 101.20M | 0 | 0 | 0 | 0.00 |
| JUNE | 4.92 | 65.69M | 0 | 0 | 0 | 0.00 |
Skye Bioscience Inc 주식(SKYE)의 최신 뉴스
Skye Bioscience chief development officer sells shares worth $97,721 By Investing.com - Investing.com South Africa
Skye Bioscience chief development officer sells shares worth $97,721 - Investing.com India
Skye Bioscience CFO Kaitlyn Arsenault sells $216,652 in stock By Investing.com - Investing.com Australia
Skye Bioscience CEO Punit Dhillon sells $413,924 in stock By Investing.com - Investing.com Canada
Skye Bioscience CEO Punit Dhillon sells $413,924 in stock - Investing.com India
Skye Bioscience director Grayson Paul A. sells $432,061 in stock - Investing.com
Analysts Set Skye Bioscience, Inc. (NASDAQ:SKYE) Target Price at $18.67 - MarketBeat
Skye Bioscience to Participate in Upcoming December Healthcare Investment Conferences - GlobeNewswire
Skye Bioscience to Present at Three Major Healthcare Investment Conferences in December | SKYE Stock News - StockTitan
Skye Bioscience achieved more than 50% targeted patient enrollment in CBeyond - Yahoo Finance
Altium Capital Management LP Adjusts Stake in Skye Bioscience Inc - GuruFocus.com
Skye Bioscience hits halfway mark in obesity drug trial - Investing.com India
Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated Cb1 Inhibitor - Marketscreener.com
Skye Bioscience hits halfway mark in obesity drug trial By Investing.com - ழ தொலைக்காட்சி
Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor - The Manila Times
Skye Bioscience's SWOT analysis: nimacimab's potential in obesity stock market - Investing.com Australia
Skye Bioscience (NASDAQ:SKYE) Trading Down 1.5%Should You Sell? - MarketBeat
(SKYE) Technical Pivots with Risk Controls - Stock Traders Daily
Skye Bioscience Reports Progress in Obesity Drug Trials - TipRanks
Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights - GlobeNewswire
Skye Bioscience (SKYE) Scheduled to Post Earnings on Thursday - MarketBeat
Skye Bioscience Demonstrates Prominent Role of Peripheral - GlobeNewswire
Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in Preclinical Model - StockTitan
Skye Bioscience (SKYE) to Release Quarterly Earnings on Thursday - MarketBeat
Skye Bioscience to Announce Third Quarter 2024 Results - GlobeNewswire
Skye Bioscience, Inc. (NASDAQ:SKYE) Short Interest Update - MarketBeat
Skye Bioscience appoints new chairman to boost governance By Investing.com - Investing.com Canada
Long Term Trading Analysis for (SKYE) - Stock Traders Daily
Skye Bioscience appoints new chairman to boost governance - Investing.com India
Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board - GlobeNewswire
Brokerages Set Skye Bioscience, Inc. (NASDAQ:SKYE) Price Target at $18.67 - MarketBeat
Skye Bioscience Approves Incentive Plan Amendments and Leadership Changes - TipRanks
Skye Bioscience (NASDAQ:SKYE) Shares Up 5.3%Still a Buy? - MarketBeat
Ex-Skye Bioscience VP's $4.9 Million Whistleblower Award Nixed - Bloomberg Law
Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences - GlobeNewswire
Opera to Announce Third Quarter 2024 Financial Results on October 29, 2024 - Quantisnow
Coldwell Banker Real Estate Expands Global Presence to Tanzania and Zanzibar - Quantisnow
Don't Sleep on Skye Bioscience—This Weight Loss Drug Could Soar - Benzinga
Scotiabank initates Skye Bioscience Inc (SKYE) stock to a Sector outperform - Knox Daily
Don’t Sleep on Skye Bioscience—This Weight Loss Drug Could Soar - MarketBeat
Novo Nordisk A/S ADR (NVO-N) QuotePress Release - The Globe and Mail
Top 10 startups in Ophthalmology in San Diego, United States in Oct, 2024 - Tracxn
3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn't Ignore - MarketBeat
Point72 Asia Singapore Pte. Ltd. Invests $222,000 in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
Skye Bioscience Inc (SKYE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Skye Bioscience Inc 주식 (SKYE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Diep Tuan Tu | Chief Development Officer |
Nov 15 '24 |
Sale |
5.55 |
85 |
472 |
101,748 |
| ARSENAULT KAITLYN | Chief Financial Officer |
Nov 18 '24 |
Sale |
4.99 |
43,206 |
215,598 |
166,342 |
| ARSENAULT KAITLYN | Chief Financial Officer |
Nov 15 '24 |
Sale |
5.55 |
190 |
1,054 |
209,548 |
| DHILLON PUNIT | Chief Executive Officer |
Nov 18 '24 |
Sale |
4.99 |
82,546 |
411,905 |
329,823 |
| DHILLON PUNIT | Chief Executive Officer |
Nov 15 '24 |
Sale |
5.55 |
364 |
2,020 |
412,369 |
| Grayson Paul A. | Director |
Nov 18 '24 |
Sale |
4.99 |
86,244 |
430,358 |
259,701 |
| Grayson Paul A. | Director |
Nov 15 '24 |
Sale |
5.55 |
307 |
1,704 |
345,945 |
1.80%
0.42%
자본화:
|
볼륨(24시간):